Less than a tenth of people that would benefit from GLP-1 drugs like Wegovy can access them, states the World Health Organization as it publishes its inaugural guidance on the therapies.
With more than one billion individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
According to projections, over two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with thorough and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant hurdles to broad access to the treatments that can help people shift significant weight, says the organization.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the production of these medications could only cover around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The guideline urges countries and companies to expand availability, through approaches including voluntary licensing.
Exclusive production rights on a key compound – the primary component of a leading brand – is due to expire in several nations in 2026.
The Way Obesity Jabs Work
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and enhance feelings of fullness so individuals eat less.
Individuals commonly begin shedding pounds in the initial weeks of commencing the regular doses.
Studies indicates users may regain a significant portion within a year of stopping the drug, when their normal food cravings return.
To be above a healthy weight elevates your chance for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects people in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
